APA (7th ed.) Citation

Longo, D., Generaux, G., Howell, B., Siler, S., Antoine, D., Button, D., . . . Watkins, P. (2017). Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials. Clinical pharmacology and therapeutics, 102(6), 961-969. https://doi.org/10.1002/cpt.711

Chicago Style (17th ed.) Citation

Longo, DM, et al. "Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials." Clinical Pharmacology and Therapeutics 102, no. 6 (2017): 961-969. https://doi.org/10.1002/cpt.711.

MLA (9th ed.) Citation

Longo, DM, et al. "Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials." Clinical Pharmacology and Therapeutics, vol. 102, no. 6, 2017, pp. 961-969, https://doi.org/10.1002/cpt.711.